Mechanism and design of allosteric activators of SIRT1

Fei Liu; Ningning Pang; Rui-Ming Xu; Na Yang

doi:10.1093/procel/pwac039

Protein Cell ›› 2023, Vol. 14 ›› Issue (5) : 387 -392. DOI: 10.1093/procel/pwac039

LETTER

Mechanism and design of allosteric activators of SIRT1

Author information +

History +

PDF (4390KB)

Cite this article

Download citation ▾

Fei Liu, Ningning Pang, Rui-Ming Xu, Na Yang. Mechanism and design of allosteric activators of SIRT1. Protein Cell, 2023, 14(5): 387-392 DOI:10.1093/procel/pwac039

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005;280:17187–95.

[2]	Cao D, Wang M, Qiu X et al. Structural basis for allosteric, substrate-dependent stimulation of SIRT1 activity by resveratrol. Genes Dev 2015;29:1316–25.

[3]	Dai H, Case AW, Riera TV et al. Crystallographic structure of a small molecule SIRT1 activator-enzyme complex. Nat Commun 2015;6:7645.

[4]	Dai H, Kustigian L, Carney D et al. SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem 2010;285:32695–703.

[5]	Guarente L. Franklin H. Epstein lecture: sirtuins, aging, and medicine. N Engl J Med 2011;364:2235–44.

[6]	Howitz KT, Bitterman KJ, Cohen HY et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425:191–6.

[7]	Hsu HC, Wang CL, Wang M et al. Structural basis for allosteric stimulation of Sir2 activity by Sir4 binding. Genes Dev 2013;27:64–73.

[8]	Hubbard BP, Gomes AP, Dai H et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013;339:1216–9.

[9]	Liu F, Yang N. Multiscale landscape of molecular mechanism of SIRT1 activation by STACs. Phys Chem Chem Phys 2020;22:826–37.

[10]	Lu Q, Wang J. Single molecule conformational dynamics of adenylate kinase: energy landscape, structural correlations, and transition state ensembles. J Am Chem Soc 2008;130:4772–83.

[11]	Milne JC, Denu JM. The Sirtuin family: therapeutic targets to treat diseases of aging. Curr Opin Chem Biol 2008;12:11–7.

[12]	Milne JC, Lambert PD, Schenk S et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007;450:712–6.

[13]	Pacholec M, Bleasdale JE, Chrunyk B et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010;285:8340–51.

[14]	Whitford PC, Miyashita O, Levy Y et al. Conformational transitions of adenylate kinase: switching by cracking. J Mol Biol 2007;366:1661–71.

[15]	Wu J, Zhang D, Chen L et al. Discovery and mechanism study of SIRT1 activators that promote the deacetylation of fluorophore-labeled substrate. J Med Chem 2013;56:761–80.